Format

Send to

Choose Destination
Leukemia. 2014 May;28(5):981-92. doi: 10.1038/leu.2013.293. Epub 2013 Oct 9.

International Myeloma Working Group recommendations for global myeloma care.

Author information

1
Department of Medicine I, Center of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria.
2
Clinica Universidad de Navarra, Pamplona, Spain.
3
Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece.
4
Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
5
Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain.
6
Parkside Cancer Centre, London, UK.
7
Columbia University Medical Center, New York, NY, USA.
8
Chaoyang Hospital, Capital Medical University, Beijing, China.
9
Shanghai Chang Zheng Hospital, Shanghai, China.
10
Department of Hematology, University Hospital, Cracow, Poland.
11
Haematology Department, Wellington Hospital, Wellington, New Zealand.
12
Department of Internal Medicine, University of Ostrava, Ostrava, Czech Republic.
13
Nagoya City Midori General Hospital, Nagoya, Japan.
14
Institute of Hematology, Royal Prince Alfred Hospital, Sydney, Australia.
15
Santa Casa de Sao Paulo, Sao Paolo, Brazil.
16
Bonco Metro Politano de Sangre, Caracas, Venezuela.
17
Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
18
University of Giessen, Giessen, Germany.
19
Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Bologna, Italy.
20
Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA.

Abstract

Recent developments have led to remarkable improvements in the assessment and treatment of patients with multiple myeloma (MM). New technologies have become available to precisely evaluate the biology and extent of the disease, including information about cytogenetics and genetic abnormalities, extramedullary manifestations and minimal residual disease. New, more effective drugs have been introduced into clinical practice, which enable clinicians to significantly improve the outcome of patients but also pose new challenges for the prevention and management of their specific side effects. Given these various new options and challenges, it is important to identify the minimal requirements for diagnosis and treatment of patients, as access to the most sophisticated advances may vary depending on local circumstances. Here, we propose the minimal requirements and possible options for diagnosis, monitoring and treatment of patients with multiple myeloma.

PMID:
24177258
DOI:
10.1038/leu.2013.293
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center